BAKER BROS. ADVISORS LP Q2 2022 Filing
Filed August 15, 2022
Portfolio Value
$17.6B
Holdings
117
Report Date
Q2 2022
Filing Type
13F-HR
All Holdings (117 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | 46,912,266 | $8.3T | 47090.61% | |
| 2 | INCYIncyte Corporation | 36,154,117 | $2.7T | 15581.95% | |
| 3 | ONCBeiGene, Ltd. | 11,668,897 | $1.9T | 10714.32% | |
| 4 | BMRNBioMarin Pharmaceutical Inc. | 7,620,494 | $631.5B | 3582.63% | |
| 5 | ACADACADIA Pharmaceuticals Inc. | 41,923,486 | $590.7B | 3351.12% | |
| 6 | ASNDAscendis Pharma A/S | 4,852,655 | $451.1B | 2559.16% | |
| 7 | ARGXargenx SE | 1,119,557 | $424.2B | 2406.41% | |
| 8 | BCRXBioCryst Pharmaceuticals, Inc. | 12,710,818 | $134.5B | 762.92% | |
| 9 | KODKodiak Sciences Inc. | 17,310,490 | $132.3B | 750.28% | |
| 10 | GBTUSDGlobal Blood Therapeutics, Inc. | 3,732,502 | $119.3B | 676.54% | |
| 11 | ABCLAbCellera Biologics Inc. | 10,450,180 | $111.3B | 631.38% | |
| 12 | MDGLMadrigal Pharmaceuticals, Inc. | 1,499,213 | $107.3B | 608.81% | |
| 13 | MRTXEURMirati Therapeutics, Inc. | 1,409,784 | $94.6B | 536.90% | |
| 14 | IMCRImmunocore Holdings plc | 2,520,730 | $94.0B | 533.55% | |
| 15 | HZNPHorizon Therapeutics Public Ltd Co | 1,148,504 | $91.6B | 519.69% | |
| 16 | CERSCerus Corporation | 16,067,558 | $85.0B | 482.20% | |
| 17 | TVTXTravere Therapeutics, Inc. | 3,300,009 | $80.0B | 453.62% | |
| 18 | REPLReplimune Group, Inc. | 3,591,081 | $62.8B | 356.11% | |
| 19 | TRDAEntrada Therapeutics, Inc. | 4,865,819 | $59.3B | 336.22% | |
| 20 | 1K0IGM Biosciences, Inc. | 3,156,102 | $56.9B | 322.83% | |
| 21 | KYMRKymera Therapeutics, Inc. | 2,879,825 | $56.7B | 321.69% | |
| 22 | KRYSKrystal Biotech, Inc. | 807,735 | $53.0B | 300.88% | |
| 23 | PRLDPrelude Therapeutics Inc. | 10,123,824 | $52.8B | 299.80% | |
| 24 | NRIXNurix Therapeutics, Inc. | 3,882,125 | $49.2B | 279.04% | |
| 25 | LEGNLegend Biotech Corporation | 856,658 | $47.1B | 267.29% | |
| 26 | ALKSAlkermes plc | 1,500,000 | $44.7B | 253.50% | |
| 27 | CCXIEURChemoCentryx, Inc. | 1,792,657 | $44.4B | 252.01% | |
| 28 | 290AChinook Therapeutics, Inc. | 2,534,102 | $44.3B | 251.44% | |
| 29 | IM8NInsmed Incorporated | 2,156,001 | $42.5B | 241.20% | |
| 30 | IMTXImmatics N.V. | 4,423,731 | $38.5B | 218.59% | |
| 31 | —DBV Technologies S.A. | 14,614,264 | $37.3B | 211.41% | |
| 32 | SRPT 1.5 11/15/24Sarepta Therapeutics, Inc. | 29,174,000 | $36.6B | 207.51% | |
| 33 | INSM 0.75 06/01/28Insmed Incorporated | 40,000,000 | $33.3B | 188.79% | |
| 34 | AVTEAerovate Therapeutics, Inc. | 2,070,010 | $32.4B | 183.55% | |
| 35 | AMRNAmarin Corporation plc | 21,169,805 | $31.5B | 178.95% | |
| 36 | VSTMVerastem, Inc. | 26,988,898 | $31.3B | 177.61% | |
| 37 | RAREUltragenyx Pharmaceutical Inc. | 470,974 | $28.1B | 159.40% | |
| 38 | TSVT*2seventy bio, Inc. | 2,062,744 | $27.2B | 154.47% | |
| 39 | KNSAKiniksa Pharmaceuticals, Ltd. | 2,799,577 | $27.1B | 153.90% | |
| 40 | BMEABiomea Fusion, Inc. | 2,104,559 | $25.2B | 143.04% | |
| 41 | ALTAltimmune, Inc. | 2,075,403 | $24.3B | 137.75% | |
| 42 | NVTA1EURInvitae Corporation | 9,873,488 | $24.1B | 136.67% | |
| 43 | PACBPacific Biosciences of California, Inc. | 5,444,963 | $24.1B | 136.53% | |
| 44 | XENEXenon Pharmaceuticals Inc. | 751,639 | $22.9B | 129.72% | |
| 45 | HRTXHeron Therapeutics, Inc. | 8,131,678 | $22.7B | 128.71% | |
| 46 | MRUSMerus N.V. | 995,397 | $22.5B | 127.85% | |
| 47 | VERVVerve Therapeutics, Inc. | 1,416,530 | $21.6B | 122.79% | |
| 48 | DSGNDesign Therapeutics, Inc. | 1,436,636 | $20.1B | 114.10% | |
| 49 | —Affimed N.V. | 6,596,830 | $18.3B | 103.66% | |
| 50 | TILInstil Bio, Inc. | 3,893,700 | $18.0B | 102.05% | |
| 51 | OTICEUROtonomy, Inc. | 8,412,634 | $17.5B | 99.27% | |
| 52 | DNLIDenali Therapeutics Inc. | 588,738 | $17.3B | 98.30% | |
| 53 | RYTMRhythm Pharmaceuticals, Inc. | 4,125,062 | $17.1B | 97.12% | |
| 54 | OPTEYOpthea Limited | 2,696,191 | $17.0B | 96.36% | |
| 55 | ADAPYAdaptimmune Therapeutics plc | 9,830,877 | $16.7B | 94.81% | |
| 56 | CRNXCrinetics Pharmaceuticals, Inc. | 827,480 | $15.4B | 87.55% | |
| 57 | 1T7Tricida, Inc. | 1,503,090 | $14.6B | 82.54% | |
| 58 | —Forma Therapeutics Holdings, Inc. | 2,024,876 | $14.0B | 79.15% | |
| 59 | FLGTFulgent Genetics, Inc. | 201,444 | $11.0B | 62.32% | |
| 60 | —bluebird bio, Inc. | 2,499,715 | $10.3B | 58.71% | |
| 61 | RLMDRelmada Therapeutics, Inc. | 495,113 | $9.4B | 53.34% | |
| 62 | —DICE Therapeutics, Inc. | 588,235 | $9.1B | 51.79% | |
| 63 | —Zymeworks Inc. | 1,708,472 | $9.1B | 51.37% | |
| 64 | KRTXKaruna Therapeutics, Inc. | 69,966 | $8.9B | 50.21% | |
| 65 | TCRXTScan Therapeutics, Inc. | 2,784,792 | $8.8B | 49.69% | |
| 66 | ANABAnaptysBio, Inc. | 427,179 | $8.7B | 49.20% | |
| 67 | FGENEURFibroGen, Inc. | 815,718 | $8.6B | 48.87% | |
| 68 | —Invitae Corporation | 10,300,000 | $8.1B | 45.88% | |
| 69 | CYTCyteir Therapeutics, Inc. | 2,643,640 | $7.9B | 44.84% | |
| 70 | SRZNSurrozen, Inc. | 2,500,000 | $7.5B | 42.55% | |
| 71 | RETAEURReata Pharmaceuticals, Inc. | 223,976 | $6.8B | 38.62% | |
| 72 | 698Achilles Therapeutics plc | 2,591,366 | $6.5B | 37.05% | |
| 73 | CBAYUSDCymaBay Therapeutics, Inc. | 2,170,464 | $6.4B | 36.32% | |
| 74 | BCELAtreca, Inc. | 3,532,760 | $6.3B | 35.88% | |
| 75 | —Talis Biomedical Corporation | 7,624,835 | $6.2B | 35.12% | |
| 76 | HRMYHarmony Biosciences Holdings, Inc. | 123,600 | $6.0B | 34.20% | |
| 77 | ATRAGBXAtara Biotherapeutics, Inc. | 744,186 | $5.8B | 32.89% | |
| 78 | VORVor Biopharma Inc. | 1,138,768 | $5.7B | 32.11% | |
| 79 | CNTACentessa Pharmaceuticals plc | 1,127,273 | $5.5B | 31.15% | |
| 80 | NKTXNkarta, Inc. | 400,000 | $4.9B | 27.96% | |
| 81 | VERAVera Therapeutics, Inc. | 333,333 | $4.5B | 25.74% | |
| 82 | RVMDRevolution Medicines, Inc. | 222,222 | $4.3B | 24.57% | |
| 83 | EWTXEdgewise Therapeutics, Inc. | 500,000 | $4.0B | 22.58% | |
| 84 | —Neoleukin Therapeutics, Inc. | 3,821,740 | $3.9B | 22.33% | |
| 85 | HOOKGBPHOOKIPA Pharma Inc. | 2,400,481 | $3.9B | 22.20% | |
| 86 | NTRANatera, Inc. | 100,000 | $3.5B | 20.11% | |
| 87 | TNGXTango Therapeutics, Inc. | 750,000 | $3.4B | 19.28% | |
| 88 | —Athira Pharma, Inc. | 1,040,834 | $3.2B | 18.01% | |
| 89 | 5E7iTeos Therapeutics, Inc. | 150,346 | $3.1B | 17.57% | |
| 90 | —Evofem Biosciences, Inc. | 2,583,616 | $2.9B | 16.56% | |
| 91 | MGNXMacroGenics, Inc. | 892,579 | $2.6B | 14.94% | |
| 92 | ALGSAligos Therapeutics, Inc. | 2,076,400 | $2.5B | 14.25% | |
| 93 | ALECAlector, Inc. | 239,228 | $2.4B | 13.79% | |
| 94 | BCABBioAtla, Inc. | 825,000 | $2.4B | 13.34% | |
| 95 | ALLKGUSDAllakos Inc. | 703,050 | $2.2B | 12.49% | |
| 96 | —TCR2 Therapeutics Inc. | 753,064 | $2.2B | 12.39% | |
| 97 | SNDXSyndax Pharmaceuticals, Inc. | 110,729 | $2.1B | 12.08% | |
| 98 | AGLEUSDAeglea BioTherapeutics, Inc. | 3,410,106 | $1.7B | 9.77% | |
| 99 | —Epizyme, Inc. | 1,000,000 | $1.5B | 8.34% | |
| 100 | AKROAkero Therapeutics, Inc. | 118,378 | $1.1B | 6.35% |
Page 1 of 2Next